Abstract：
BACKGROUND:In recent decades, clinical trials have played an increasingly important role in determining how we practice. Trial results proving that a clinical finding poses risk have led to interventions that try to reduce risk. Clinical trials proving that a particular therapy provides better outcome than another therapy have changed the therapies we now use. Unfortunately, the results of clinical trials are too often affected by biases or design issues that may overtly or covertly alter the results or the way they should really be used. In addition, these biases and design and analysis issues are rarely evident in the abstract sections or key figures and tables in the publications reporting the trials, which may be all the busy physician either reads or remembers. METHODS AND MATERIALS:This manuscript discusses the issues involved in optimally understanding clinical trial design and interpretation so that practitioners can better understand how to intelligently read and apply trial results to clinical practice. CONCLUSIONS:Clinical trial results can not be properly applied without consideration of trial design features and intertrial comparisons.
journal_name
J Cardiovasc Pharmacol Therjournal_title
Journal of cardiovascular pharmacology and therapeuticsauthors
Reiffel JAdoi
10.1177/107424840000500103keywords:
subject
Has Abstractpub_date
2000-01-01 00:00:00pages
17-25issue
1eissn
1074-2484issn
1940-4034pii
S1074248400000055journal_volume
5pub_type
杂志文章abstract：:Ischemia-reperfusion injury is a composite of the injury sustained during a period of reduced or absent blood flow to a tissue or organ and the additional insult sustained on reperfusion, which limits the amount of tissue that can be salvaged. Ischemia-reperfusion injury is the predominant insult during kidney transpl...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章,评审
doi：10.1177/1074248417702893
更新日期：2017-07-01 00:00:00
abstract：:Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist remains a mainstay in the prevention of ischemic events following coronary stent placement. Significant controversy exists regarding the optimal management of high platelet reactivity despite antiplatelet therapy; however this finding has been cons...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章,评审
doi：10.1177/1074248415571456
更新日期：2015-07-01 00:00:00
abstract：:Phosphodiesterase inhibitors as inodilators in heart failure are associated with promotion of arrhythmias. Calcium sensitizers have been proposed for the treatment of severe decompensated heart failure. The effect of levosimendan, a calcium sensitizer, and milrinone, a phosphodiesterase inhibitor, on ventricular arrhy...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章
doi：10.1177/1074248406289286
更新日期：2006-06-01 00:00:00
abstract：:BACKGROUND: The tendency for the electrophysiologic effect of class III antiarrhythmic agents (action potential prolongation) to be diminished at faster heart rates represents a major drawback of this class of drug and is usually referred to as "reverse use dependence." A novel class III agent, MS-551, has recently be...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章
doi：10.1177/107424849700200105
更新日期：1997-01-01 00:00:00
abstract：:Platelets are key mediators in the pathophysiology of atherothrombotic disease. Inappropriate platelet activation can lead to thrombosis and ischemic events. Platelet function testing has been used to monitor patient response to antiplatelet therapy. Variability in response to antiplatelet therapy may be due in part t...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章,评审
doi：10.1177/1074248409339309
更新日期：2009-09-01 00:00:00
abstract：:BACKGROUND: Digoxin improves baroreflex function and reduces neurohumoral activation in severe heart failure, but it is uncertain how digoxin affects ventricular remodeling and progression to left ventricular dysfunction. In addition, the effect of digoxin in in vitro beta-adrenoceptor density and function, and contra...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章
doi：10.1177/107424849800300403
更新日期：1998-10-01 00:00:00
abstract：:Postischemic accumulation of intracellular Na+ promotes calcium overload and contributes to cellular necrosis. Cardioprotection afforded by pharmacologic blockade of the sodium-hydrogen exchanger subtype 1 (NHE1) is thought to be more remarkable than that obtained by ischemic conditioning (IC). The window of protectio...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章
doi：10.1177/1074248418755120
更新日期：2018-05-01 00:00:00
abstract：:Recently, cyclooxygenase-2 (COX-2) inhibitors (coxibs), a class of drugs intended to be painkillers, have created unprecedented controversy because of their cardiovascular risk profile. The controversy has affected the patients, health-care providers, the Food and Drug Administration, and the manufacturers of these ag...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章,评审
doi：10.1177/107424840501000203
更新日期：2005-06-01 00:00:00
abstract：BACKGROUND:Brief periods of reocclusion (postconditioning) during early reperfusion reduce myocardial infarct size. Whether postconditioning has an effect on lethal ventricular arrhythmias independent of infarction in an in-vivo regional ischemia model is unknown. The purpose of this study was to determine if postcondi...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章
doi：10.1177/107424840601100105
更新日期：2006-03-01 00:00:00
abstract：:Despite initial promising reports that anti-inflammatory properties of cycloxygenase-2 (COX-2) inhibitors may confer anti-atherosclerosis effects and stabilize the atherosclerotic plaque, subsequent data from long-term clinical trials have shown that selective COX-2 inhibitors are associated with increased risk of car...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章,评审
doi：10.1177/1074248407301172
更新日期：2007-06-01 00:00:00
abstract：:Dosing equivalency of carvedilol and metoprolol remains a debate. Degree of beta 1-blockade is best assessed by blunting of the exercise-induced heart rate. Accordingly, the authors have investigated dosing equivalency by examining baseline and peak exercise heart rates and norepinephrine levels in subjects with chron...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章
doi：10.1177/1074248407312629
更新日期：2008-03-01 00:00:00
abstract：:The results of numerous long-term, randomized trials show that statins significantly decrease the risks of myocardial infarction, stroke, and vascular death as well as total mortality. The benefits of statins on cardiovascular disease in patients who are not experiencing acute coronary syndromes generally become appar...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章,评审
doi：10.1177/107424840400900i109
更新日期：2004-03-01 00:00:00
abstract：OBJECTIVE:To investigate the effect of a pharmacist care program on cardiovascular risks in type 2 diabetic patients. METHODS:A 9-month, prospective, randomized, controlled study was conducted in a public hospital in Hong Kong. Patients in the intervention group had regular drug-counseling sessions with pharmacists in...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章,随机对照试验
doi：10.1177/1074248410396216
更新日期：2012-03-01 00:00:00
abstract：BACKGROUND:Omapatrilat has potent enzymatic inhibitory effects on the angiotensin-converting enzyme and neutral endopeptidase. The prolonged effects of this inhibition on systemic and regional hemodynamics, cardiovascular mass, and hydroxyproline concentration in spontaneously hypertensive rats were studied. The contri...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章
doi：10.1177/107424840300800210
更新日期：2003-06-01 00:00:00
abstract：:The National Heart, Lung, and Blood Institute convened a Workshop on September 20-21, 2010, "New Horizons in Cardioprotection," to identify future research directions for cardioprotection against ischemia and reperfusion injury. Since the early 1970s, there has been evidence that the size of a myocardial infarction co...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type：
doi：10.1177/1074248411402501
更新日期：2011-09-01 00:00:00
abstract：:Ventricular remodeling is a compensatory response that comprises the processes of apoptosis, muscle cell hypertrophy, and rearrangement of the extracellular matrix fibers connecting the muscles. These processes are associated with transformation of endothelium and/or fibroblasts to myofibroblasts. Neutral matrix metal...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章,评审
doi：10.1177/107424840200700407
更新日期：2002-10-01 00:00:00
abstract：:A large body of evidence indicates that a persistently high heart rate is associated with a significant risk for higher mortality and sudden death in individuals with a variety cardiovascular disorders, as well as in the general population. Heart rates elevated beyond a certain threshold have been found to be a risk f...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章,评审
doi：10.1177/107424840200700208
更新日期：2002-04-01 00:00:00
abstract：:Although COVID-19 is viewed primarily as a respiratory disease, cardiovascular risk factors and disease are prevalent among infected patients and are associated with worse outcomes. In addition, among multiple extra-pulmonary manifestations, there has been an increasing recognition of specific cardiovascular complicat...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章
doi：10.1177/1074248420982736
更新日期：2020-12-17 00:00:00
abstract：:Prior studies have suggested that intravenous diltiazem reduces the probability of spontaneous conversion of atrial fibrillation (AF) to sinus rhythm in the electrophysiology laboratory and in patients with postoperative AF. Whether diltiazem exerts the same effect in patients presenting to the emergency department (E...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章,随机对照试验
doi：10.1177/1074248407303792
更新日期：2007-09-01 00:00:00
abstract：BACKGROUND AND OBJECTIVES:Myocardial hypertrophy is a common clinical finding leading to heart failure and sudden death. Mitofusin 2 (Mfn2), a hyperplasia suppressor protein, is downregulated in hypertrophic heart. This study examined the role of Mfn2 in myocardial hypertrophy and its potential signal pathway. METHODS...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章
doi：10.1177/1074248410385683
更新日期：2011-06-01 00:00:00
abstract：:Dronedarone is a new antiarrhythmic drug for patients with nonpermanent atrial fibrillation (AF). A relatively consistent finding in all trials studying dronedarone was a moderate but significant elevation of serum creatinine. Since dronedarone competes for the same organic cation transporter in the distal renal tubul...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章
doi：10.1177/1074248412453873
更新日期：2013-03-01 00:00:00
abstract：:Catestatin (CST), which is emerging as a novel cardiac modulator, can protect the heart against excessive sympathetic drive in hypertensive cardiomyopathy. The aim of this study is to investigate whether exogenous CST decreases excessive cardiac sympathetic drive and improves autonomic function and exerts cardioprotec...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章
doi：10.1177/1074248416628676
更新日期：2016-11-01 00:00:00
abstract：BACKGROUND:Beta-Cyclodextrin tetradecasulfate binds fibroblast growth factors and possesses anticoagulant properties. This study was designed to assess the separate and combined effects of local intramural delivery and intravenous administration of beta-cyclodextrin tetrade-casulfate on neointimal formation and arteria...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章
doi：10.1177/107424840300800i108
更新日期：2003-03-01 00:00:00
abstract：:The effects of nitric oxide (NO) and noradrenergic activation in the posterior hypothalamus on arterial pressure tolerance induced by subcutaneous injection of nitroglycerin (NTG) was investigated in anesthetized Sprague-Dawley rats. Intravenous injections of NTG (3, 10, and 30 microg/kg) and sodium nitroprusside (1, ...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章
doi：10.1177/1074248407313832
更新日期：2008-06-01 00:00:00
abstract：:BACKGROUND: The effectiveness of antisense oligodeoxynucleotides for in vitro and in vivo studies is limited by a low efficiency of cellular uptake and instability due to degradation by nucleases. To overcome some of these problems, we recently developed a transfer method that utilizes inactivated Sendai virus (hemagg...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章
doi：10.1177/107424849700200308
更新日期：1997-07-01 00:00:00
abstract：BACKGROUND:Dystrophin-deficient cardiomyopathy is a growing clinical problem without targeted treatments. We investigated whether nicorandil promotes cardioprotection in human dystrophin-deficient induced pluripotent stem cell (iPSC)-derived cardiomyocytes and the muscular dystrophy mdx mouse heart. METHODS AND RESULT...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章
doi：10.1177/1074248416636477
更新日期：2016-11-01 00:00:00
abstract：:BACKGROUND: We determined if a single administration of heparin or nonanticoagulant N-acetylheparin could reduce myocardial injury resulting from a 90-minute occlusion of the left circumflex coronary artery (LCX) and 6 hours of reperfusion in the anesthetized canine. METHODS AND RESULTS: Heparin (2 mg/kg), N-acetylhep...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章
doi：10.1053/jcpt.1996.0219
更新日期：1996-07-01 00:00:00
abstract：:Dofetilide is a class III antiarrhythmic agent approved by the Food and Drug Administration for the conversion of atrial fibrillation and atrial flutter and maintenance of sinus rhythm in symptomatic patients with persistent arrhythmia. Drug trials showed neutral mortality in post-myocardial infarction patients and th...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章,评审
doi：10.1177/1074248418784288
更新日期：2019-01-01 00:00:00
abstract：BACKGROUND:The well-described morning peak in the onset of acute coronary syndromes has been partly attributed to increased platelet activity upon arising. It has been suggested that stent thrombosis (ST) exhibits a similar pattern. We assessed whether a diurnal variation in ST occurs, and whether more robust antiplate...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章,随机对照试验
doi：10.1177/1074248413497534
更新日期：2013-11-01 00:00:00
abstract：:Lidocaine-sensitive, repetitive atrial tachycardia is an uncommon arrhythmia. The electrophysiologic substrate is still unknown, and the pharmacologic responses have not been fully explored. The aim of this study was to investigate the effects of intravenous adenosine and verapamil in patients with lidocaine-sensitive...
journal_title：Journal of cardiovascular pharmacology and therapeutics
pub_type： 杂志文章
doi：10.1177/1074248411418971
更新日期：2012-06-01 00:00:00
